We found that a panel of CD117 with a cut-off of 10% tumor cell expression, BAP1, mTAP, and TdT was able to predict 88.9% of thymic carcinomas and 77.8% of thymomas (among the studied types A and B3 thymomas and micronodular thymomas with lymphoid stroma). Here, KIT is linked to thymic carcinoma.